Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Frontline Nivolumab Plus Ipilimumab Reduces Symptomatic Burden in MSI-H/dMMR mCRC

June 28th 2024

HRQOL data from the CheckMate 8HW trial may support the use of nivolumab and ipilimumab as first-line treatment for patients with MSI-H or dMMR metastatic colorectal cancer.

Lunresertib Plus FOLFIRI Shows Safety, Elicits Responses in CCNE1+ or FBXW7+ Advanced GI Tumors

June 27th 2024

Lunresertib plus FOLFIRI was safe and produced responses in advanced gastrointestinal tumors harboring CCNE1 amplifications or FBXW7 alterations.

MPO Could Represent Predictive OS Biomarker for CM24 Plus Nivolumab/Chemo in Second-Line PDAC

June 27th 2024

MPO may be a predictive biomarker for survival for treatment with CM24, nivolumab, and chemotherapy in second-line pancreatic ductal adenocarcinoma.

Lutetium Lu 177 Dotatate Enters the Pediatric Treatment Paradigm for SSTR+ GEP-NETs

June 27th 2024

Daniel M. Halperin, MD, details the FDA approval of lutetium Lu 177 dotatate as well as safety and efficacy data in pediatric and adult patients treated with the agent.

Lutetium Lu 177 Dotatate Maintains PFS, ORR Benefits Across Subgroups in SSTR+ GEP-NETs

June 26th 2024

Lutetium Lu 177 dotatate with octreotide led to a clinical benefit in PFS and ORR regardless of tumor grade or primary origin in advanced grade 2 and grade 3 GEP-NETs.

Dr Trent on the Efficacy of Bezuclastinib Plus Sunitinib in Pretreated GIST

June 26th 2024

Jonathan C. Trent, MD, PhD discusses bezuclastinib plus sunitinib in gastrointestinal stromal tumors with imatinib resistance or intolerance.

Clinical Considerations for 2L Treatment Sequencing in mCRC

June 26th 2024

Key opinion leaders outline their strategies for sequencing second-line treatments in chemotherapy-refractory metastatic colorectal cancer patients, considering the influence of previous therapies on their decision-making process.

Overview of Molecular Testing and Barriers in mCRC

June 26th 2024

The panel of CRC experts explores the significance of molecular testing for mCRC patients, emphasizing recommended biomarkers and optimal testing timelines.

Dr Garcia-Carbonero on the Phase 2b VIRAGE Trial in Metastatic PDAC

June 24th 2024

Rocio Garcia-Carbonero, MD, discusses the rationale for the phase 2b VIRAGE trial in patients with metastatic pancreatic cancer.

Dr King on the Need for Less-Toxic Therapies in Advanced Gastrointestinal Cancers

June 24th 2024

Daniel King, MD, PhD, discusses the need to develop less-toxic regimens for advanced gastrointestinal cancers.

Camrelizumab Plus Rivoceranib vs Sorafenib as First-Line Therapy for Unresectable Hepatocellular Carcinoma (uHCC): Final Overall Survival Analysis of the Phase 3 CARES-310 Study

June 24th 2024

This is a final overall survival analysis on the phase 3 CARES-310 study (NCT03764293), a randomized, open-label, international phase 3 trial comparing camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC).

Dr Pant on the Utility of Zanidatamab in Previously Treated HER2+ Biliary Tract Cancer

June 20th 2024

Shubham Pant, MD, MBBS, discusses the utility of zanidatamab in patients with previously treated HER2+ biliary tract cancer.

Dr Kunz on Time to Response With Lutetium Lu 177 Dotatate in GEP-NETs

June 13th 2024

Pamela L. Kunz, MD, discusses a subanalysis of the NETTER-2 study investigating frontline lutetium Lu 177 dotatate in advanced, well-differentiated GEP-NETs.

Dr Kamath on the Rationale for Investigating Early-Onset vs Average-Onset PDAC

June 12th 2024

Suneel Kamath, MD, discusses the rationale for conducting an investigation into the tumor microbiome differences between early- and average-onset PDAC.

NGC-Cap Demonstrates Preliminary Efficacy in Stage III/IV GI Cancer

June 12th 2024

Next generation capecitabine led to positive preliminary efficacy results in patients with stage III or IV gastrointestinal tract cancer.

Frontline Toripalimab Plus Bevacizumab Improves PFS, OS in Advanced HCC

June 12th 2024

Frontline toripalimab plus bevacizumab improved progression-free survival and overall survival vs sorafenib in patients with advanced hepatocellular carcinoma.

Amphiphile Lymph Node–Targeted Vaccine Is Safe and Bolsters T-Cell Responses in MRD+ PDAC and CRC

June 11th 2024

The strength of mKRAS-specific T-cell responses produced by ELI-002 7P correlated with tumor biomarker responses in pancreatic and colorectal cancer.

Dr Cecchini on the Initial Efficacy of CM24 Plus Nivolumab and NALIRIFOX in Advanced PDAC

June 10th 2024

Michael Cecchini, MD, discusses interim data on the use of CM24 with nivolumab and NALIRIFOX in advanced/metastatic pancreatic ductal adenocarcinoma.

Dr Kamath on the Tumor Microbiome of Early- and Average-Onset PDAC

June 10th 2024

Suneel Kamath, MD, discusses tumor microbiome differences between early-onset and average-onset pancreatic adenocarcinoma.

China’s NMPA Accepts BLA for Zanidatamab in HER2+ Biliary Tract Cancer

June 10th 2024

China’s National Medical Products Administration has accepted the biologics license application for zanidatamab in second-line HER2+ biliary tract cancer.